Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
CardioVascular and Interventional Radiology
Erschienen in: CardioVascular and Interventional Radiology 1/2016

01.01.2016 | Review

Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications

verfasst von: Fei Sun, Verónica Crisóstomo, Claudia Báez-Díaz, Francisco M. Sánchez

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Pathological features of benign prostatic hyperplasia (BPH) dictate various responses to prostatic artery embolization (PAE). Typically, BPH originates in the transition zone and periurethral region, where should be considered the primary target area in PAE procedures. Given that histological heterogeneity of components in hyperplasia nodules, epithelial or stromal, identifying the more responsive nodules to PAE will have clinical implications. Since some lower urinary tract symptoms (LUTS) in patients with BPH are usually related to bladder outlet obstruction-induced changes in bladder function rather than to outflow obstruction directly, proper selection of candidate patients prior to PAE is of great clinical importance. BPH is a typical chronic progressive condition, suggesting PAE could aim not only to relieve LUTS but also to delay or prevent the clinical progression. Awareness of the pathological background of BPH is essential for interventional radiologists to improve clinical outcomes and develop new treatment strategies in clinical practice of PAE.
Literatur
1.
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.PubMed
2.
Pisco J, Campos Pinheiro L, Bilhim T, Duarte M, RioTinto H, Fernandes L, Vaz Santos V, Oliveira AG. Prostatic arterial embolization for benign prostatic hyperplasia: short- and intermediate-term results. Radiology. 2013;266(2):668–77.PubMedCrossRef
3.
Carnevale FC, da Motta-Leal-Filho JM, Antunes AA, Baroni RH, Marcelino AS, Cerri LM, Yoshinaga EM, Cerri GG, Srougi M. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol. 2013;24(4):535–42.PubMedCrossRef
4.
Bagla S, Martin CP, van Breda A, Sheridan MJ, Sterling KM, Papadouris D, Rholl KS, Smirniotopoulos JB, van Breda A. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014;25(1):47–52.PubMedCrossRef
5.
Carnevale FC, Moreira AM, Antunes AA. The “PErFecTED technique”: proximal embolization first, then embolize distal for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2014;37(6):1602–5.PubMedCrossRef
6.
Golzarian J, Antunes AA, Bilhim T, Carnevale FC, Konety B, McVary KT, Parsons JK, Pisco JM, Siegel DN, Spies J, Wasserman N, Gowda N, Ahrar K. Prostatic artery embolization to treat lower urinary tract symptoms related to benign prostatic hyperplasia and bleeding in patients with prostate cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2014;25(5):665–74.PubMedCrossRef
7.
Roehrborn CG. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 10th ed. Philadelphia: Saunders; 2012. p. 2570–610.CrossRef
8.
Madersbacher S, Klingler HC, Schatzl G, Stulnig T, Schmidbauer CP, Marberger M. Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol. 1996;156(5):1662–7.PubMedCrossRef
9.
10.
Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987;317(10):599–604.PubMedCrossRef
11.
Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology. 1984;114(6):2100–6.PubMedCrossRef
12.
Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Pt 1):1399–403.PubMedCrossRef
13.
Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol. 1991;145(2):405–9.PubMed
14.
Sonke GS, Mochtar CA, Kiemeney LALM. Etiology of benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 2570–610.
15.
Niu Y, Xu Y, Zhang J, Bai J, Yang H, Ma T. Proliferation and differentiation of prostatic stromal cells. BJU Int. 2001;87(4):386–93.PubMedCrossRef
16.
Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res. 1996;222(1):103–10.PubMedCrossRef
17.
Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology. 1998;139(11):4672–8.PubMed
18.
Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1(3):157–62.PubMedCrossRef
19.
Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8(1):29–36.PubMedCrossRef
20.
Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999;53(3 Suppl 3a):1–6.PubMedCrossRef
21.
Ghafar MA, Puchner PJ, Anastasiadis AG, Cabelin MA, Buttyan R. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep. 2002;3(4):292–6.PubMedCrossRef
22.
Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer AE, Bartsch G, Frauscher F. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96(7):1073–8.PubMedCrossRef
23.
Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006;98(5):1038–42.PubMedCrossRef
24.
Deipolyi AR, Al-Ansari S, Khademhosseini A, Oklu R. Occlusion of the internal iliac artery is associated with smaller prostate and decreased urinary tract symptoms. J Vasc Interv Radiol. 2015;26(9):1305–10.PubMedCrossRef
25.
Claus S, Wrenger M, Senge T, Schulze H. Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res. 1993;21(5):305–8.PubMedCrossRef
26.
McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968;49(3):347–57.PubMed
27.
Myers RP. Structure of the adult prostate from a clinician’s standpoint. Clin Anat. 2000;13(3):214–5.PubMedCrossRef
28.
29.
McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978;15(4):340–5.PubMed
30.
McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 1990;17(3):477–86.PubMed
31.
Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 1979;122(4):487–91.PubMed
32.
Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K. Racial differences in cellular composition of benign prostatic hyperplasia. Prostate. 2001;49(4):243–50.PubMedCrossRef
33.
Robert M, Costa P, Bressolle F, Mottet N, Navratil H. Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens. Br J Urol. 1995;75(3):317–24.PubMedCrossRef
34.
Lepor H, Shapiro E, Wang B, Liang YC. Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian-American men. Urology. 1996;47(1):38–42.PubMedCrossRef
35.
Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol. 1992;147(5):1293–7.PubMed
36.
Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 1992;21(4):297–307.PubMedCrossRef
37.
Bostwick DG. The pathology of benign prostatic hyperplasia. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 97–111.
38.
Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol. 1989;141(2):243–7.PubMed
39.
Lynch TH, Waymont B, Dunn JA, Hughes MA, Wallace DM. Rapid diagnostic service for patients with haematuria. Br J Urol. 1994;73(2):147–51.PubMedCrossRef
40.
Hasan ST, German K, Derry CD. Same day diagnostic service for new cases of haematuria–a district general hospital experience. Br J Urol. 1994;73(2):152–4.PubMedCrossRef
41.
Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, Holmes SA. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163(2):496–8.PubMedCrossRef
42.
Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. BJU Int. 2000;85(1):70–3.PubMedCrossRef
43.
Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24(2):220–6.PubMedCrossRef
44.
Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Prostate. 1995;26(3):111–5.PubMedCrossRef
45.
Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol. 1996;155(2):595–600.PubMedCrossRef
46.
Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol. 2000;163(1):107–13.PubMedCrossRef
47.
Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161(4):1174–9.PubMedCrossRef
48.
EzzelDin K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Rosette JJ. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology. 1996;48(3):393–7.CrossRef
49.
Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 1993;150(2 Pt 1):351–8.PubMed
50.
Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481–7.PubMedCrossRef
51.
Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999;162(4):1301–6.PubMedCrossRef
52.
McVary KT. Prostatic arterial embolization for LUTS/BPH-an opportunity for collaborative research or next prostatic gizmo candidate? J Urol. 2014;191(3):577–8.PubMedCrossRef
53.
Lepor H. Editorial comment to: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Stoner E and the Members of the Finasteride Study Group. Urology. 1994; 43(3): 292–293.
54.
Charlton RG, Morley AR, Chambers P, Gillespie JI. Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int. 1999;84(9):953–60.PubMedCrossRef
55.
O’Reilly BA, Kosaka AH, Chang TK, Ford AP, Popert R, McMahon SB. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int. 2001;87(7):617–22.PubMedCrossRef
56.
Levin RM, Haugaard N, O’Connor L, Buttyan R, Das A, Dixon JS, Gosling JA. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000;19(5):609–29.PubMedCrossRef
57.
Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep. 2005;6(6):410–8.PubMedCrossRef
58.
Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol. 1979;121(5):640–2.PubMed
59.
Rollema HJ, Van Mastrigt R. Improved indication and followup in transurethral resection of the prostate using the computer program CLIM: a prospective study. J Urol. 1992;148(1):111–5.PubMed
60.
Lemack GD, McConnell JD. Bladder responses to obstruction. In: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. 2nd ed. Oxfordshire: Taylor & Francis; 2005. p. 113–8.
61.
George NJ, Feneley RC, Roberts JB. Identification of the poor risk patient with “prostatism” and detrusor failure. Br J Urol. 1986;58(3):290–5.PubMedCrossRef
62.
Kaplan SA, Bowers DL, Te AE, Olsson CA. Differential diagnosis of prostatism: A 12-year retrospective analysis of symptoms, urodynamics and satisfaction with therapy. J Urol. 1996;155(4):1305–8.PubMedCrossRef
Metadaten
Titel
Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications
verfasst von
Fei Sun
Verónica Crisóstomo
Claudia Báez-Díaz
Francisco M. Sánchez
Publikationsdatum
01.01.2016
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 1/2016
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-015-1233-x

Weitere Artikel der Ausgabe 1/2016

CardioVascular and Interventional Radiology 1/2016 Zur Ausgabe

Review

Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver

Case Report

Digestive Tract Complications of Renal Cryoablation

Clinical Investigation

Patient Satisfaction After Femoral Arterial Access Site Closure Using the ExoSeal® Vascular Closure Device Compared to Manual Compression: A Prospective Intra-individual Comparative Study

Brief Communication

In Vivo Proof of Superselective Transarterial Chemoembolization with 40-μm Drug-Eluting Beads in a Patient with Hepatocellular Carcinoma

Letter to the Editor

Hyponatremia Following High-Volume D5W Hydrodissection During Thermal Ablation

Clinical Investigation

Percutaneous Augmented Peripheral Osteoplasty in Long Bones of Oncologic Patients for Pain Reduction and Prevention of Impeding Pathologic Fracture: The Rebar Concept

Neu im Fachgebiet Radiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise